207 related articles for article (PubMed ID: 36178335)
1. Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor.
Tack J; Vladimirov B; Horny I; Chong CF; Eisner J; Czerniak R; Takanami Y
Neurogastroenterol Motil; 2023 Jan; 35(1):e14468. PubMed ID: 36178335
[TBL] [Abstract][Full Text] [Related]
2. Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan.
Sakurai K; Suda H; Fujie S; Takeichi T; Okuda A; Murao T; Hasuda K; Hirano M; Ito K; Tsuruta K; Hattori M
Dig Dis Sci; 2019 Mar; 64(3):815-822. PubMed ID: 30415407
[TBL] [Abstract][Full Text] [Related]
3. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
[TBL] [Abstract][Full Text] [Related]
4. Differences Between Patients with Heartburn Refractory to Vonoprazan and Those Refractory to Proton Pump Inhibitors.
Matsumura T; Sonoda M; Okimoto K; Dao HV; Takahashi S; Akizue N; Horio R; Goto C; Kurosugi A; Kaneko T; Ohta Y; Taida T; Kikuchi A; Fujie M; Kato J; Kato N
Dig Dis Sci; 2024 Jun; 69(6):2132-2139. PubMed ID: 38622462
[TBL] [Abstract][Full Text] [Related]
5. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients.
Davidson G; Wenzl TG; Thomson M; Omari T; Barker P; Lundborg P; Illueca M
J Pediatr; 2013 Sep; 163(3):692-8.e1-2. PubMed ID: 23800403
[TBL] [Abstract][Full Text] [Related]
7. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.
Miwa H; Igarashi A; Teng L; Uda A; Deguchi H; Tango T
J Gastroenterol; 2019 Aug; 54(8):718-729. PubMed ID: 30919071
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Placebo-Controlled
Sierra-Arango F; Castaño DM; Forero JD; Pérez-Riveros ED; Ardila Duarte G; Botero ML; Cárdenas A; De la Hoz-Valle J
Can J Gastroenterol Hepatol; 2019; 2019():3926051. PubMed ID: 31929980
[TBL] [Abstract][Full Text] [Related]
9. Pilot, Randomized, Blinded, Placebo-Controlled Trial Investigating the Correlation Between Acid Control and Heartburn Relief with 14 Days of Esomeprazole Treatment.
Miner PB; Johnson DA; Katz PO; Li J; Gatoulis SC; Pollack C
Adv Ther; 2018 Nov; 35(11):2024-2040. PubMed ID: 30255418
[TBL] [Abstract][Full Text] [Related]
10. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
Oshima T; Arai E; Taki M; Kondo T; Tomita T; Fukui H; Watari J; Miwa H
Aliment Pharmacol Ther; 2019 Jan; 49(2):140-146. PubMed ID: 30589965
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease.
Niikura R; Yamada A; Hirata Y; Hayakawa Y; Takahashi A; Shinozaki T; Takeuchi Y; Fujishiro M; Koike K
Intern Med; 2018 Sep; 57(17):2443-2450. PubMed ID: 29607951
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study.
Lim H; Park JK; Chung H; Lee SH; Park JM; Park JH; Kim GH; Shin SK; Hong SJ; Lee KJ; Park MI; Jung HK; Kim HS; Sung JK; Jeon SW; Choi SC; Moon JS; Kim N; Park JJ; Hong SH; Kim NY; Jung HY
BMC Gastroenterol; 2023 Dec; 23(1):447. PubMed ID: 38110901
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD.
Yokoya Y; Igarashi A; Uda A; Deguchi H; Takeuchi T; Higuchi K
J Gastroenterol; 2019 Dec; 54(12):1083-1095. PubMed ID: 31396703
[TBL] [Abstract][Full Text] [Related]
14. Randomised clinical trial: Efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease.
Fass R; Vaezi M; Sharma P; Yadlapati R; Hunt B; Harris T; Smith N; Leifke E; Armstrong D
Aliment Pharmacol Ther; 2023 Nov; 58(10):1016-1027. PubMed ID: 37750406
[TBL] [Abstract][Full Text] [Related]
15. Gastroesophageal Acid Reflux Control 5 Years After Antireflux Surgery, Compared With Long-term Esomeprazole Therapy.
Hatlebakk JG; Zerbib F; Bruley des Varannes S; Attwood SE; Ell C; Fiocca R; Galmiche JP; Eklund S; Långström G; Lind T; Lundell LR;
Clin Gastroenterol Hepatol; 2016 May; 14(5):678-85.e3. PubMed ID: 26226096
[TBL] [Abstract][Full Text] [Related]
16. Reflux episodes detected by impedance in patients on and off esomeprazole: a randomised double-blinded placebo-controlled crossover study.
Moawad FJ; Betteridge JD; Boger JA; Cheng FK; Belle LS; Chen YJ; Maydonovitch CL; Wong RK
Aliment Pharmacol Ther; 2013 May; 37(10):1011-8. PubMed ID: 23560727
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.
Simadibrata DM; Lesmana E; Fass R
J Gastroenterol Hepatol; 2024 May; 39(5):796-805. PubMed ID: 38263507
[TBL] [Abstract][Full Text] [Related]
18. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety.
Vakil NB; Shaker R; Johnson DA; Kovacs T; Baerg RD; Hwang C; D'Amico D; Hamelin B
Aliment Pharmacol Ther; 2001 Jul; 15(7):927-35. PubMed ID: 11421866
[TBL] [Abstract][Full Text] [Related]
19. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.
Fock KM; Teo EK; Ang TL; Chua TS; Ng TM; Tan YL
World J Gastroenterol; 2005 May; 11(20):3091-8. PubMed ID: 15918196
[TBL] [Abstract][Full Text] [Related]
20. GERD assessment including pH metry predicts a high response rate to PPI standard therapy.
Kandulski A; Peitz U; Mönkemüller K; Neumann H; Weigt J; Malfertheiner P
BMC Gastroenterol; 2013 Jan; 13():12. PubMed ID: 23324360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
